Lack of Early Change in Disease Activity Score Predicts the Likelihood of Achieving Low Disease Activity at Month 6: Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naive Patients with Rheumatoid Arthritis

被引：0
|
作者：
Keystone, Edward [1 ]
van Vollenhoven, Ronald F. [2 ]
Wilkinson, Bethanie [3 ]
Fallon, Lara [4 ]
Hwang, Lie-Ju [5 ]
Chapman, Douglass [5 ]
DeMasi, Ryan [5 ]
Lee, Eun Bong [6 ]
机构：
[1] Mt Sinai Hosp, Toronto, ON, Canada
[2] Amsterdam Rheumatol & Immunol Ctr, Amsterdam, Netherlands
[3] Pfizer Inc, Groton, CT 06340 USA
[4] Pfizer Canada, Montreal, PQ, Canada
[5] Pfizer Inc, New York, NY USA
[6] Seoul Natl Univ, Seoul, South Korea
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1608
引用
收藏
页数：2
相关论文
共 50 条
  • [1] LACK OF EARLY CHANGE IN DISEASE ACTIVITY SCORE PREDICTS THE LIKELIHOOD OF ACHIEVING LOW DISEASE ACTIVITY AT MONTH 6: TOFACITINIB MONOTHERAPY VERSUS METHOTREXATE IN METHOTREXATE-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS
    Keystone, E.
    van Vollenhoven, R. F.
    Wilkinson, B.
    Fallon, L.
    Hwang, L. -J.
    Chapman, D.
    DeMasi, R.
    Lee, E. B.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 250 - 250
  • [2] Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6
    van Vollenhoven, Ronald F.
    Lee, Eun Bong
    Fallon, Lara
    Zwillich, Samuel H.
    Wilkinson, Bethanie
    Chapman, Douglass
    DeMasi, Ryan
    Keystone, Edward
    ARTHRITIS CARE & RESEARCH, 2019, 71 (01) : 71 - 79
  • [3] Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
    Fleischmann, Roy M.
    Huizinga, Tom W. J.
    Kavanaugh, Arthur F.
    Wilkinson, Bethanie
    Kwok, Kenneth
    DeMasi, Ryan
    van Vollenhoven, Ronald F.
    RMD OPEN, 2016, 2 (02):
  • [4] Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naive Patients with Rheumatoid Arthritis: Radiographic, Clinical and Functional Comparison
    Fleischmann, R. M.
    Lee, E. B.
    Hall, S.
    Wilkinson, B. E.
    Bradley, John D.
    Gruben, D.
    Koncz, T.
    Krishnaswami, S.
    Wallenstein, G.
    Zwillich, S. H.
    van Vollenhoven, R. F.
    ARTHRITIS AND RHEUMATISM, 2013, 65 (12): : 3323 - 3323
  • [5] Radiographic, Clinical and Functional Comparison of Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naive Patients with Rheumatoid Arthritis.
    Lee, Eun Bong
    Fleischmann, Roy M.
    Hall, Stephen
    van Vollenhoven, Ronald F.
    Bradley, John
    Gruben, David
    Koncz, Tamas
    Krishnaswami, Sriram
    Wallenstein, Gene
    Zwillich, Samuel H.
    Wilkinson, Bethanie E.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S1049 - S1049
  • [6] Periodontal Evaluation Is Associated with Increased Likelihood of Achieving Low Disease Activity in Rheumatoid Arthritis with Methotrexate
    Rohr, Melanie
    O'Dell, James R.
    Danve, Abhijeet
    Sayles, Harlan
    Thiele, Geoffrey M.
    Payne, Jeffrey
    Mikuls, Ted R.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [7] Identification of Distinct Disease Activity Trajectories in Methotrexate-Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty-Four Months
    Bykerk, Vivian P.
    Lee, Eun Bong
    Vollenhoven, Ronald
    Gruben, David C.
    Fallon, Lara
    Woolcott, John C.
    Keystone, Edward
    ARTHRITIS CARE & RESEARCH, 2022, 74 (01) : 131 - 141
  • [8] Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naive Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study
    Takeuchi, Tsutomu
    Rischmueller, Maureen
    Blanco, Ricardo
    Xavier, Ricardo M.
    Ueki, Yukitaka
    Atsumi, Tatsuya
    Chen, Su
    Friedman, Alan
    Pangan, Aileen L.
    Strand, Vibeke
    van Vollenhoven, Ronald F.
    MODERN RHEUMATOLOGY, 2021, 31 (03) : 534 - 542
  • [9] TOFACITINIB MONOTHERAPY IS EFFECTIVE IN METHOTREXATE-NAIVE PATIENTS WITH DISEASE DURATION LESS THAN 6 MONTHS: A POST-HOC ANALYSIS OF EARLY RHEUMATOID ARTHRITIS SUBJECTS IN A PHASE 3 TRIAL
    Huizinga, T. W. J.
    Fleischmann, R.
    van Vollenhoven, R.
    Gruben, D.
    Wilkinson, B.
    Koncz, T.
    Bradley, J.
    Zwillich, S. H.
    Benda, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 241 - 241
  • [10] Tofacitinib and Adalimumab Achieve Similar Rates of Low Disease Activity in Rheumatoid Arthritis-Lack of Improvement in Disease Activity Score by 3 Months Predicts Low Likelihood of Low Disease Activity At 1 Year
    van Vollenhoven, Ronald F.
    Krishnaswami, Sriram
    Benda, Birgitta
    Gruben, David
    Wilkinson, Bethanie
    Mebus, Charles A.
    Zwillich, Samuel H.
    Bradley, John
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S556 - S556
12345